Hereditary Cancers

Myriad myRisk Hereditary Cancer Logo

Myriad myRisk™ Hereditary Cancer is a 25-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on eight primary cancer sites.

Myriad BRACAnalysis logo

The BRACAnalysis ® test assesses a person’s risk of developing hereditary breast or ovarian cancer based on the detection of mutations in the BRCA1 and BRCA2 genes.

Myriad COLARIS logo

COLARIS® testing assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine/endometrial cancer by detecting disease-causing mutations in the MLH1, MSH2, MSH6 and PMS2 genes.

Myriad COLARIS AP logo

COLARIS AP ® testing assesses a person’s risk of developing hereditary colorectal polyps and cancer by detecting mutations in the APC and MYH genes.

Myriad MELARIS logo

MELARIS® testing assesses a person’s risk of developing hereditary melanoma by detecting inherited mutations in the p16 gene (also called CDKN2A or INK4A ).

Myriad PANEXIA logo

PANEXIA® testing assesses a person’s risk of developing hereditary pancreatic cancer by analyzing the PALB2 and BRCA2 genes, which are most commonly mutated in families with hereditary pancreatic cancer.

Lung Cancer

Myriad myPlan Lung Cancer logo

Myriad myPlan™ Lung Cancer is a molecular diagnostic test that measures the expression levels of cell cycle progression genes to provide an accurate assessment of cancer aggressiveness in early-stage non-small cell lung cancer.

Melanoma

Myriad myPath melanoma logo

Myriad myPath™ Melanoma is a unique molecular diagnostic test that analyzes 23 genes to assist in the timely and accurate diagnosis of melanoma.

Prostate Cancer

Prolaris for prostate cancer logo

Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris® can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.

Rheumatoid Arthritis

Vectra DA logo

Vectra® DA is a multi-biomarker molecular blood test that simultaneously measures 12 key biomarkers to provide an objective and reproducible measure of rheumatoid arthritis (RA) disease activity.

Other Products

Myriad PREZEON logo

PREZEON® testing assesses loss of PTEN  function in cancer patients, which is associated with more aggressive disease progression and poorer survival rates.